Patent · US Active

Chimeric antigen receptors targeting CD70

US12152081B2 · kind B2 · utility

0Cited by
65References
42Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 17, 2022
Grant dateNov 26, 2024
Priority date
Expiry dateJul 7, 2042

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2319/33
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The disclosure provides CARs (CARs) that specifically bind to CD70. The disclosure further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The disclosure further relates to therapeutic methods for use of these CARs and engineered immune cells comprising these CARs for the treatment of a condition associated with malignant cells expressing CD70 (e.g., cancer).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.